# Phase 3 Study of Sofosbuvir and Ribavirin

> **NCT01497366** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 527 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Sofosbuvir
- **DRUG:** PEG
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT01497366
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-01
- **Final completion:** 2013-04
- **Target enrollment:** 527 (ACTUAL)
- **Last updated:** 2014-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01497366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01497366, "Phase 3 Study of Sofosbuvir and Ribavirin". Retrieved via AI Analytics 2026-06-20 from https://api.ai-analytics.org/clinical/NCT01497366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*